Olga R. Chávez-Alexander-Anderson
Research Subjects
Olga R. Chávez-Alexander-Anderson has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Anna Barbara Emilia Zimmermann
Clinic for Radiation Oncology and Medical Oncology, University Animal Hospital, Vetsuisse Faculty, University of Zurich, 8057 Zurich, Switzerland
1 shared publication - Anna M. Schmoker
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, USA
1 shared publication - Colin J. Hartman
Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, 621 Rubin Building—HB7936, 1 Medical Center Drive, Lebanon, NH 03756, USA
1 shared publication - Daniel Luna Dávalos
VETCONNECT Diagnóstico por Imagen, Monterrey 64780, Mexico
1 shared publication - Hugo Arias-Pulido
Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Lebanon, NH 03756, USA
1 shared publication - Jay L. Rothstein
Lifordi Immunotherapeutics, Lebanon, NH 03756, USA
1 shared publication
Latest Publications
- Open Access
Characterization of Anti-Canine PD-1 Antibodies
Cancer is a leading cause of death in dogs, and incidence rates in dogs exceed those in humans. Current therapeutic options for canine cancer patients remain limited, with most treatments focused on palliative care. Immune checkpoint inhibitors such as anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies that have transformed cancer therapy and expanded the therapeutic options in humans could offer the same clinical benefit in canine cancer patients. This study details the engineering and functional characterization of mouse and chimeric mouse–canine anti-canine PD-1 (cPD-1) monoclonal antibodies. We demonstrate that anti-cPD-1 antibodies block the interaction between cPD-1 and its ligand cPD-L1, thereby inhibiting this immune signaling pathway. In a proof-of-concept study in seven companion canine cancer patients, intratumoral therapy with the lead anti-cPD-1 antibody (HugPetmab) was safe, well-tolerated, had no observed adverse events, and showed evidence of tumor control in a subset of injected tumors. These findings support the potential of HugPetmab antibody as an immunotherapeutic option for treating canine cancer patients.
Open AccessCharacterization of Anti-Canine PD-1 Antibodies
Cancer is a leading cause of death in dogs, and incidence rates in dogs exceed those in humans. Current therapeutic options for canine cancer patients remain limited, with most treatments focused on palliative care. Immune checkpoint inhibitors such as anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies that have transformed cancer therapy and expanded the therapeutic options in humans could offer the same clinical benefit in canine cancer patients. This study details the engineering and functional characterization of mouse and chimeric mouse–canine anti-canine PD-1 (cPD-1) monoclonal antibodies. We demonstrate that anti-cPD-1 antibodies block the interaction between cPD-1 and its ligand cPD-L1, thereby inhibiting this immune signaling pathway. In a proof-of-concept study in seven companion canine cancer patients, intratumoral therapy with the lead anti-cPD-1 antibody (HugPetmab) was safe, well-tolerated, had no observed adverse events, and showed evidence of tumor control in a subset of injected tumors. These findings support the potential of HugPetmab antibody as an immunotherapeutic option for treating canine cancer patients.